V-Bio Ventures

Co-founders and managing partners Christina Takke and Willem Broekaert lead the investment team. Both have deep operating and venture backgrounds in European life sciences and previously managed the seed fund at VIB, the Flemish Institute for Biotechnology, where the firm originates most of its proprietary pipeline.

The firm relies on an exclusive relationship with VIB, a research institute with over 1,800 scientists across five Flemish universities. V-Bio Ventures embeds within the tech-transfer process, working with researchers before company formation to shape IP strategy and recruit leadership — an arrangement that limits competition from outside investors at the seed stage.

V-Bio Ventures is an independent venture capital firm, not a corporate venture arm, though it maintains a strategic sourcing partnership with VIB. The firm raises discretionary third-party capital from LPs and makes independent investment decisions — VIB is a pipeline partner, not a controlling sponsor.

V-Bio Ventures focuses on seed and Series A rounds, with reserve allocations for follow-on investment through Series B. The firm acts as a founding or first institutional investor in the majority of its portfolio companies, which are typically 12–24 months post-spinout from academic labs.

V-Bio Ventures conducts direct equity investments and does not publicly operate as a fund-of-funds or commit to other venture managers. Its vehicles are structured to hold board seats and actively support portfolio companies alongside co-investing syndicate partners.